Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/458720 http://scihub22266oqcxt.onion/10.1155/2015/458720 C4442291!4442291!26078807     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oxid+Med+Cell+Longev 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26078807|t=2015. Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?|pdf=|usr=}}{{26078807}} gab.com Text Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease JO: Oxid Med Cell Longev http://www.kidney.de/pget.php?&tw=1&pmid=26078807 #FOAvip Fibrotic diseases including chronic kidney disease, liver cirrhosis, idiopathic pulmonary fibrosis, and chronic disease account for 45% mortality in the developed countries and pose a great threat to the global health. Many great targets and molecules have been reported to be involved in the initiation and/or progression of fibrosis, among which inflammation and oxidative stress are well-recognized modulation targets. Hydrogen sulfide (H2S) is the third gasotransmitter with potent properties in inhibiting inflammation and oxidative stress in various organs. Recent evidence suggests that plasma H2S level is decreased in various animal models of fibrotic diseases and supplement of exogenous H2S is able to ameliorate fibrosis in the kidney, lung, liver, and heart. This leads us to propose that modulation of H2S production may represent a promising therapeutic venue for the treatment of a variety of fibrotic diseases. Here, we summarize and discuss the current data on the role and underlying mechanisms of H2S in fibrosis diseases related to heart, liver, kidney, and other organs. Twit Text FOAVip Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease ????Oxid Med Cell Longev http://www.kidney.de/pget.php?&tw=1&pmid=26078807 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26078807 #FOAvip English Wikipedia <ref>{{Cite pmid|26078807}}</ref> Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease? #MMPMID26078807 Song K; Li Q; Yin XY; Lu Y; Liu CF; Hu LF Oxid Med Cell Longev 2015[]; 2015 (ä): ä PMID26078807show ga Fibrotic diseases including chronic kidney disease, liver cirrhosis, idiopathic pulmonary fibrosis, and chronic disease account for 45% mortality in the developed countries and pose a great threat to the global health. Many great targets and molecules have been reported to be involved in the initiation and/or progression of fibrosis, among which inflammation and oxidative stress are well-recognized modulation targets. Hydrogen sulfide (H2S) is the third gasotransmitter with potent properties in inhibiting inflammation and oxidative stress in various organs. Recent evidence suggests that plasma H2S level is decreased in various animal models of fibrotic diseases and supplement of exogenous H2S is able to ameliorate fibrosis in the kidney, lung, liver, and heart. This leads us to propose that modulation of H2S production may represent a promising therapeutic venue for the treatment of a variety of fibrotic diseases. Here, we summarize and discuss the current data on the role and underlying mechanisms of H2S in fibrosis diseases related to heart, liver, kidney, and other organs. äHydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?(epmc).pdf DeepDyve Pubget Overpricing